Sumitomo Life Insurance’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.36M Buy
48,600
+1,059
+2% +$28.2K 0.03% 159
2025
Q4
$1.18M Buy
47,541
+575
+1% +$14.5K 0.03% 176
2025
Q3
$1.2M Sell
46,966
-1,707
-4% -$42.1K 0.04% 165
2025
Q2
$1.18M Sell
48,673
-2,829
-5% -$66K 0.08% 161
2025
Q1
$1.31M Sell
51,502
-516
-1% -$13.5K 0.05% 160
2024
Q4
$1.38M Sell
52,018
-1,452
-3% -$39.4K 0.03% 162
2024
Q3
$1.55M Buy
53,470
+1,305
+3% +$38.1K 0.03% 146
2024
Q2
$1.46M Sell
52,165
-6,742
-11% -$186K 0.03% 149
2024
Q1
$1.63M Sell
58,907
-2,318
-4% -$64.3K 0.04% 143
2023
Q4
$1.76M Sell
61,225
-3,114
-5% -$94.1K 0.05% 126
2023
Q3
$2.13M Sell
64,339
-859
-1% -$30.4K 0.06% 89
2023
Q2
$2.39M Sell
65,198
-6,297
-9% -$245K 0.11% 75
2023
Q1
$2.92M Sell
71,495
-525
-0.7% -$22.7K 0.25% 55
2022
Q4
$3.69M Sell
72,020
-672
-0.9% -$32.2K 0.27% 37
2022
Q3
$3.18M Sell
72,692
-8,870
-11% -$431K 0.13% 43
2022
Q2
$4.28M Buy
81,562
+1,609
+2% +$82K 0.12% 37
2022
Q1
$4.14M Sell
79,953
-1,279
-2% -$66.4K 0.1% 43
2021
Q4
$4.8M Sell
81,232
-2,398
-3% -$119K 0.11% 36
2021
Q3
$3.6M Sell
83,630
-3,534
-4% -$157K 0.1% 52
2021
Q2
$3.41M Sell
87,164
-13,424
-13% -$522K 0.11% 55
2021
Q1
$3.64M Sell
100,588
-55,153
-35% -$1.96M 0.15% 56
2020
Q4
$5.73M Sell
155,741
-21,929
-12% -$804K 0.24% 30
2020
Q3
$6.19M Hold
177,670
0.29% 28
2020
Q2
$5.51M Sell
177,670
-1,825
-1% -$62K 0.3% 27
2020
Q1
$5.56M Buy
179,495
+2,961
+2% +$101K 0.4% 23
2019
Q4
$6.56M Sell
176,534
-1,739
-1% -$61.9K 0.74% 28
2019
Q3
$6.08M Sell
178,273
-23,016
-11% -$837K 0.79% 27
2019
Q2
$8.27M Buy
201,289
+7,580
+4% +$301K 0.98% 19
2019
Q1
$7.8M Sell
193,709
-20,213
-9% -$809K 1.05% 15
2018
Q4
$8.86M Buy
213,922
+15,065
+8% +$625K 1.23% 14
2018
Q3
$8.31M Sell
198,857
-15,191
-7% -$585K 1% 16
2018
Q2
$7.37M Buy
214,048
+19,782
+10% +$676K 0.9% 17
2018
Q1
$6.54M Sell
194,266
-8,620
-4% -$296K 0.86% 17
2017
Q4
$6.97M Buy
202,886
+7,553
+4% +$258K 0.87% 20
2017
Q3
$6.62M Sell
195,333
-3,556
-2% -$114K 0.84% 21
2017
Q2
$6.34M Buy
198,889
+8,432
+4% +$266K 0.83% 22
2017
Q1
$6.18M Sell
190,457
-42,053
-18% -$1.33M 0.87% 21
2016
Q4
$7.17M Buy
232,510
+5,167
+2% +$158K 1.02% 19
2016
Q3
$7.31M Sell
227,343
-10,544
-4% -$353K 1.08% 13
2016
Q2
$7.95M Sell
237,887
-22,684
-9% -$724K 1.09% 14
2016
Q1
$7.33M Sell
260,571
-20,528
-7% -$586K 0.95% 22
2015
Q4
$8.61M Sell
281,099
-18,177
-6% -$572K 1.09% 14
2015
Q3
$8.92M Buy
299,276
+19,402
+7% +$622K 1.18% 11
2015
Q2
$8.9M Sell
279,874
-34,632
-11% -$1.13M 1.08% 11
2015
Q1
$10.4M Sell
314,506
-33,289
-10% -$1.06M 1.15% 9
2014
Q4
$10.3M Sell
347,795
-19,513
-5% -$560K 1.02% 13
2014
Q3
$10.3M Sell
367,308
-9,803
-3% -$275K 1.01% 14
2014
Q2
$10.6M Sell
377,111
-44,397
-11% -$1.27M 1.02% 13
2014
Q1
$12.8M Sell
421,508
-39,305
-9% -$1.17M 1.25% 9
2013
Q4
$13.4M Sell
460,813
-51,761
-10% -$1.51M 1.21% 11
2013
Q3
$14M Sell
512,574
-61,099
-11% -$1.66M 1.3% 11
2013
Q2
$15.2M Buy
+573,673
New +$15.9M 1.46% 9

Other funds holding PFE

Sumitomo Life Insurance's PFE Position: Q1 2026 in Review

Sumitomo Life Insurance increased its Pfizer (PFE) stake by 2.2% in Q1 2026, buying an estimated $28.2K and bringing the position to 48,600 shares worth $1.36M. The position accounts for 0.03% of the portfolio, ranked #159.

Sumitomo Life Insurance first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.2M in Q2 2013. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Sumitomo Life Insurance held 48,600 shares of Pfizer worth $1.36M as of Q1 2026.
  • Sumitomo Life Insurance bought 1,059 Pfizer shares in Q1 2026, an estimated $28.2K.
  • Pfizer made up 0.03% of Sumitomo Life Insurance's portfolio in Q1 2026, its #159 holding.
  • Sumitomo Life Insurance first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Sumitomo Life Insurance's Pfizer position peaked at $15.2M in Q2 2013.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Sumitomo Life Insurance's 13F filing for Q1 2026, filed 12 May 2026.